4th Japanese Safety Pharmacology Society (JSPS) Annual Meeting
Program (DRAFT)  
As of Dec.3

Date: February 15 (Fri) -16 (Sat), 2013  
Venue: The University of Tokyo, Yayoi Auditorium, Ichijo Hall / Annex  
President: Katsuyoshi Chiba, PhD (Daiichi Sankyo Co., Ltd.)

Day 1 (February 15)  
(Yayoi Auditorium, Ichijo Hall)

10:00 – 17:00  
Poster Sessions (Yayoi Auditorium, Annex)

10:00 – 10:10  
Opening

Opening remarks (Katsuyoshi Chiba, President of 4th Annual Meeting)

10:10 – 12:00  
Symposium 1 [Cardiovascular system]

Current trends and issues of safety pharmacology studies on the cardiovascular systems

(Takashi Yoshinaga, Eisai Co., Ltd.)

2. Characteristic of in vivo studies using dogs on the cardiovascular systems  
(Akira Takahara, Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University)

3. Usefulness of monkeys as animal models for cardiovascular diseases  
(Naohide Ageyama, Tsukuba Primate Research Center, National Institute of Biomedical Innovation)

4. Current trends and issues of safety pharmacological evaluation on the cardiovascular systems in combination with general toxicity studies  
(Ken Meecham, Huntingdon Life Sciences Ltd.)

13:30 – 14:20  
Educational Lecture 1 [Central nervous system]

Basis for understanding the central nervous system adverse effects  
(Norio Matsuki, Laboratory of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, The University of Tokyo)
14:30 – 16:10  Symposium 2 [Central nervous system]
Approach for detecting the CNS adverse effects associated with pharmaceuticals

1. Diversity and predictability of CNS adverse effects from a clinical standpoint
   (Hisatsugu Miyata, Department of Psychiatry, The Jikei University School of Medicine)
2. Evaluation methods of CNS adverse effects in mouse
   (Tsuyoshi Miyagawa, Divisions of Systems Medical Science, Institute for Comprehensive Medical
   Science, Fujita Health University)
3. Issues and future vision of FOB test system as the predictive methods for CNS adverse effects
   (Ikuo Horii, Phizer Inc. / Showa University)

16:30 – 17:50  Overseas Invited Speakers

1. Results from the SPS industry survey on safety pharmacology included in toxicology studies
   (Simon Authier, CIToxLAB North America) From SPS Board of Directors
2. Situation of research on iPS-derived cardiomyocytes/neuron with regard to application to
   safety assessment including the regulatory (FDA) perspective
   (Blake Anson, Cellular Dynamics International)
3. Title: TBD
   (TBD)

18:30 –  Banquet Party  (Sanjo Conference Hall)

Day 2 (February 16)
(Yayoi Auditorium, Ichijo Hall)

9:00 – 15:00  Poster Sessions  (Yayoi Auditorium, Annex)
   Poster Discussion (10:50 - 11:40)

8:30 – 10:40  Oral Sessions
   Two tracks of presentation
   1st track: Yayoi Auditorium, Ichijo Hall
   2nd track: Faculty of Agriculture, building number 1st

11:50 – 12:50  Lunchtime Seminar
   Under the sponsorship of Sophion Bioscience A/S and Primetech

1. Title: TBD
   (Sophion Bioscience A/S)
2. Title: TBD
   (Primetech)
13:10 – 14:00  Educational Lecture 2 [Ion Channel]

The TRP ion channel family and safety pharmacology: From basics to current research
(Makoto Tominaga, Division of Cell Signaling, Okazaki Institute for Integrative Bioscience, National Institutes of Natural Sciences)

14:00 – 15:00  Symposium 3 [Cardiovascular risk assessment]

Current trends and issues of cardiovascular risk assessment in clinical

1. Cardiovascular safety assessment in anti-diabetic drug development programs:
   Meeting the challenges associated with this paradigm shift
   (Prabhaker Viswanathan, Takeda Global Research & Development Center, Inc.)

2. Drug-induced cardiotoxicity in clinical: Focus on anti-cancer drug
   (Toru Maruyama, Institute of Health Science, Kysuhu University)

15:20 – 16:50  Symposium 4 [From clinical to clinical research]

Importance of safety pharmacology research and bridging to clinical research

1. The correlation between clinical toxicities and non-clinical findings in safety pharmacology
   (Takako Ohkura, Maruishi Pharmaceutical Co.Ltd. / Non-clinical Evaluation Expert Committee, Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association)

2. Roles of translational medicine in reducing phase2 attrition, the most critical issue
   in pharmaceutical R&D
   (Yoichi Kurebayashi, Division of Integrated Drug Discovery Sciences, Graduate School of Medicine, Kobe University)

3. A new efficacy of a drug discovered by chance during the safety pharmacology studies
   (Atsushi Sugiyama, Department of Pharmacology, Faculty of Medicine, Toho University)

17:00 – 17:40  Special Invited Lecture

Title: TBD
(Taku Nagao, Former food safety commission)

17:40 – Closing

JSPS award ceremony (Mitsuyasu Tabo, Chair of JSPS Award Selection Committee)
Closing remarks (Hiroyuki Tashibu, President of 5th Annual Meeting)